384 research outputs found
NARRAR LO ‘INDECIBLE’: LA CONSTRUCCIÓN RETÓRICA EN TRES NOVELAS TESTIMONIO DE EX-DESAPARECIDOS: TEJAS VERDES (HERNÁN VALDÉS), DECIDME CÓMO ES UN ÁRBOL (MARCOS ANA) Y 2922 DÍAS MEMORIA DE UN PRESO DE LA DICTADURA (EDUARDO JOZAMI).
No full textMaria Alessandra Giovannini analiza de forma comparativa y contrastiva tres experiencias de detención y desaparición. Tras una larga introducción teórica sobre la relación entre testimonio y autobiografía, la investigadora profundiza las modalidades de construcción del yo narrativo en tres obras testimoniales: Tejas verdes del chileno Hernán Valdés, Decidme cómo es un árbol del español Marcos Ana y 2922 días. Memoria de un preso de la dictadura del argentino Eduardo Jozami. Gracias al estudio de las funciones del narrador y de la arquitectura paratextual, Giovannini evidencia las problemáticas implícitas en todo acto de transcripción de vidas cruzadas por eventos traumáticos y violentos
Deferasirox (Exjade®) for the treatment of iron overload
No full textDeferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis. Copyright © 2009 S. Karger AG, Basel.Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056-NEJM199807023390102; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Bennett JM, 2008, AM J HEMATOL, V83, P858, DOI 10.1002-ajh.21269; Beutler E, 2007, BLOOD CELL MOL DIS, V39, P140, DOI 10.1016-j.bcmd.2007.03.009; Cappellini M. D., 2008, BLOOD, V112, P3875; Cappellini MD, 2007, CLIN THER, V29, P909, DOI 10.1016-j.clinthera.2007.05.007; Cappellini MD, 2008, HAEMATOL-HEMATOL J, V93, P336; CAPPELLINI MD, 2008, BLOOD, V112, P3878; Cappellini MD, 2007, BLOOD, V110, p816A; Cappellini MD, 2008, BLOOD, V112, P5411; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Claster S, 2003, BRIT MED J, V327, P1151, DOI 10.1136-bmj.327.7424.1151; Cohen AR, 2008, BLOOD, V111, P583, DOI 10.1182-blood-2007-08-109306; COSSU P, 1981, EUR J PEDIATR, V137, P267, DOI 10.1007-BF00443255; Daar S, 2009, EUR J HAEMATOL, V82, P454, DOI 10.1111-j.1600-0609.2008.01204.x; Damanhouri G, 2008, BLOOD, V112, P5409; *DIAM BLACKF AN SU, DIAM BLACKF AN SYNDR; Esposito BP, 2003, BLOOD, V102, P2670, DOI 10.1182-blood-2003-03-0807; Galanello R, 2003, J CLIN PHARMACOL, V43, P565, DOI 10.1177-0091270003253350; Galanello R, 2006, HAEMATOL-HEMATOL J, V91, P1343; Garbowski M, 2008, BLOOD, V112, P116; Gattermann N, 2005, HEMATOL ONCOL CLI S1, V19, P1; Gattermann N, 2008, BLOOD, V112, P633; Goubran HA, 2007, BLOOD, V110, p676A; GREENBERG PL, 2008, BLOOD, V112, P5083; Hellstrom-Lindberg E, 2005, SEMIN HEMATOL, V42, pS10, DOI 10.1053-j.seminhematol.2005.01.002; Ibrahim AS, 2007, J CLIN INVEST, V117, P2649, DOI 10.1172-JCI32338; International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA, V256, P1749; Jastaniah W, 2008, PEDIATR BLOOD CANCER, V50, P319, DOI 10.1002-pbe.21260; Kostler E, 2005, EXPERT OPIN PHARMACO, V6, P377, DOI 10.1517-14656566.6.3.377; LEE JW, 2008, BLOOD, V112, P439; LIST AF, 2008, BLOOD, V112, P634; Marsh JCW, 2003, BRIT J HAEMATOL, V123, P782, DOI 10.1046-j.1365-2141.2003.04721.x; MIN YH, 2008, BLOOD, V112, P3649; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Nisbet-Brown E, 2003, LANCET, V361, P1597, DOI 10.1016-S0140-6736(03)13309-0; *NOV PHARM CORP, EXJ DEF PRESCR INF N; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056-NEJM199409013310903; Olivieri NF, 1997, BLOOD, V89, P739; OLIVIERI NF, 1992, BLOOD, V79, P2741; Origa R, 2008, HAEMATOL-HEMATOL J, V93, P1095, DOI 10.3324-haematol.12484; PENNELL D, 2008, BLOOD, V112, P3874; Pennell DJ, 2008, BLOOD, V112, P3873; Pietrangelo A, 2007, BLOOD, V110, p788A; PIETRANGELO A, 2009, J HEPATOL UNPUB; Piga A, 2006, HAEMATOL-HEMATOL J, V91, P873; Piga A, 2008, BLOOD, V112, P3883; PIGA A, 2008, BLOOD, V112, P5413; PORTER JB, 2008, BLOOD, V112, P1048; PORTER JB, 2008, BLOOD, V112, P1419; Porter JB, 2008, BLOOD, V112, P3881; Porterfield D, 2005, WEED TECHNOL, V19, P1, DOI 10.1614-WT-02-006; Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111-j.1600-0609.2007.00985.x; Taher A, 2009, EUR J HAEMATOL, V82, P458, DOI 10.1111-j.1600-0609.2009.01228.x; Taher A, 2006, BLOOD CELL MOL DIS, V37, P12, DOI 10.1016-j.bcmd.2006.04.005; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; Vichinsky E, 2005, AM J HEMATOL, V80, P70, DOI 10.1002-ajh.20402; VICHINSKY E, 2008, BLOOD, V112, P1420; Vichinsky E, 2008, ACTA HAEMATOL-BASEL, V119, P133, DOI 10.1159-000125550; Vichinsky E, 2008, AM J HEMATOL, V83, P398, DOI 10.1002-ajh.21119; Wood JC, 2008, BLOOD, V112, P3882; Wood JC, 2006, TRANSL RES, V148, P272, DOI 10.1016-j.trsl.2006.05.005; ZURLO MG, 1989, LANCET, V2, P2726222
Waiting Times in Simulated Stock Markets
No full textExploiting a precise reproduction of a stock exchange, the robustness of the Continuous Double Auction (CDA) mechanism, evaluated by means of the waiting time distributions, has been proved versus 36 different set ups made by varying both the operators' behaviour and the market micro structure. The obtained results demonstrate that the CDA remains able to clear strongly different order flows, though the Milan stock exchange seemed to be a little more efficient than the NYSE under the allocative point of view, witnessing the intrinsic complexity of the stock market. The simulation has been built as an Agent Based Model in order to obtain a plausible order flow. The decisions of single agents and their interaction through the market book are realistic and reproduce some empirical analysis results. The mentioned results have been obtained either by the analysis of the complete pending time series and the same computation of the asks and bids series alone.Waiting times; Agent Based Modeling; Stock Market; Micro structures; Market Architectures
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
No full textBackground: Chronic iron overload from frequent blood transfusions to treat patients with severe anaemias leads to significant morbidity and mortality. While deferoxamine, the current standard of care, is an effective iron chelator, it requires subcutaneous infusion for 8-12 h- day, 5-7 days-week. This regimen is problematic and impacts significantly on patients' daily life. Objective: To evaluate the efficacy and tolerability of deferasirox, a once-daily oral iron chelator. Method: To review the available data reported in peer-reviewed journals (using PubMed) and at medical conferences. Results-conclusions: Deferasirox is effective in reducing or maintaining iron burden in patients with transfusion-dependent anaemias. As deferasirox is orally administered, the inconvenience of parenteral administration with deferasirox is avoided. Deferasirox improves patient satisfaction and is expected to improve compliance with iron chelation therapy. © 2008 Informa UK Ltd.Abdelrazik N, 2007, HEMATOLOGY, V12, P577, DOI 10.1080-10245330701521614; Aydinok Y, 1999, ACTA HAEMATOL-BASEL, V102, P17, DOI 10.1159-000040962; Borgna-Pignatti C, 1998, ANN NY ACAD SCI, V850, P227, DOI 10.1111-j.1749-6632.1998.tb10479.x; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056-NEJM199409013310902; Cappellini MD, 2007, CLIN THER, V29, P909, DOI 10.1016-j.clinthera.2007.05.007; CAPPELLINI MD, 2007, BLOOD, V110; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Ceci A, 2002, BRIT J HAEMATOL, V118, P330, DOI 10.1046-j.1365-2141.2002.03554.x; COHEN AR, 2006, HEMATOLOGY AM SOC HE, V42; Cohen AR, 2003, BLOOD, V102, P1583, DOI 10.1182-blood-2002-10-3280; Cunningham MJ, 2004, BLOOD, V104, P34, DOI 10.1182-blood-2003-09-3167; DAAR S, 2006, BLOOD, V108; Delea TE, 2007, TRANSFUSION, V47, P1919, DOI 10.1111-j.1537-2995.2007.01416.x; ELEFTHERIOU P, 2006, HAEMATOLOGICA S1, V91; Gabutti V, 1996, ACTA HAEMATOL-BASEL, V95, P26; Galanello R, 2006, HAEMATOL-HEMATOL J, V91, P1241; Galanello R, 2003, J CLIN PHARMACOL, V43, P565, DOI 10.1177-0091270003253350; Galanello R, 2006, HAEMATOL-HEMATOL J, V91, P1343; Gattermann N, 2005, HEMATOL ONCOL CLI S1, V19, P18; Gattermann N, 2007, LEUKEMIA RES, V31, pS109, DOI 10.1016-S0145-2126(07)70199-6; Glickstein H, 2006, BLOOD, V108, P3195, DOI 10.1182-blood-2006-05-020867; Karnon J, 2008, CURR MED RES OPIN, V24, P1609, DOI 10.1185-03007990802077442; Leitch HA, 2007, LEUKEMIA RES, V31, pS7, DOI 10.1016-S0145-2126(07)70460-5; MAHINDRA A, 2007, BLOOD, V110; Nick H, 2003, CURR MED CHEM, V10, P1065, DOI 10.2174-0929867033457610; Nick H, 2007, SEMIN HEMATOL, V44, pS12, DOI 10.1053-j.seminhematol.2007.03.005; Nick H, 2002, ADV EXP MED BIOL, V509, P185; Nisbet-Brown E, 2003, LANCET, V361, P1597, DOI 10.1016-S0140-6736(03)13309-0; *NOV PHARM AG, 2006, EXJ DEF SUMM PROD CH; *NOV PHARM AG, 2006, EXJ BAS PRESCR INF; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056-NEJM199907083410207; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056-NEJM199409013310903; Olivieri NF, 1997, BLOOD, V89, P739; Otto-Duessel M, 2007, EXP HEMATOL, V35, P1069, DOI 10.1016-j.exphem.2007.04.001; PIETRANGELO A, 2007, BLOOD, V110; Piga A, 2006, HAEMATOL-HEMATOL J, V91, P873; PLATZBECKER U, 2007, IMPACT TRANSFUSION D, V110; Porter JB, 2005, BLOOD, V106; PORTER JB, 2007, BLOOD, V110; Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111-j.1600-0609.2007.00985.x; Rose C, 2007, BLOOD, V110; ROSE C, 2006, HAEMATOLOGICA S1, V91; TAHER A, 2007, HAEMATOLOGICA S1, V92; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; Vichinsky E, 2008, ACTA HAEMATOL-BASEL, V119, P133, DOI 10.1159-000125550; Vichinsky E, 2008, AM J HEMATOL, V83, P398, DOI 10.1002-ajh.21119; Wood J, 2007, BLOOD, V110; Wood JC, 2006, TRANSL RES, V148, P272, DOI 10.1016-j.trsl.2006.05.005; 1999, FERRIPROX SUMMARY PR18171
Optical properties of nanostructured antiviral and anticancer drugs
No full textWe present a computational study on the optical absorption properties of some systems of interest in the field of drug delivery. In particular we considered as drug molecules favipiravir (T705, an antiviral molecule) and 5-fluorouracil (5FU, an anticancer molecule) and, on the other hand, pure fullerenes (C-24, B12N12, Ga12N12) and doped fullerenes (C23B, CB11N12) are considered as nanocarriers. Some combined configurations between the drug molecules and the carrier nanostructures have been then studied. The optical absorption properties of the above mentioned drug molecules and their carrier nanostructures in the free and bound states are obtained by a TD-DFT method, in gas phase and in aqueous solution. We perform a detailed analysis of the modifications arising in the absorption spectra that take place in some linked configurations between the drug molecules and the carrier nanostructures. These changes could be of importance as an optical fingerprint of the realized drug/carrier link
Hypercoagulability in non-transfusion-dependent thalassemia
No full textBeta (β)-thalassemia is characterized by a hypercoagulable state and an increased risk of thrombosis, which can result in significant morbidity and mortality. The molecular and cellular mechanisms contributing to hypercoagulability are diverse and include chronic platelet activation, alteration of red blood cell membranes, abnormal expression of adhesion molecules on vascular endothelial cells, and dysregulation of hemostasis. Regular transfusions decrease the risk of thrombosis, whereas splenectomy significantly increases the risk. Splenectomized adults with non-transfusion-dependent thalassemia are also at high risk for ischemic brain damage. Strategies to lower the risk of thrombosis should be considered, including transfusion therapy to raise hemoglobin levels and avoidance or delay of splenectomy. © 2012 Elsevier Ltd.Ataga KI, 2007, BRIT J HAEMATOL, V139, P3, DOI 10.1111-j.1365-2141.2007.06740.x; Atichartakarn V, 2002, BRIT J HAEMATOL, V118, P893, DOI 10.1046-j.1365-2141.2002.03711.x; Atichartakarn V, 2003, INT J HEMATOL, V77, P299, DOI 10.1007-BF02983790; BORENSTAINBENYASHAR V, 1993, AM J HEMATOL, V44, P63; Pignatti CB, 1998, ACTA HAEMATOL-BASEL, V99, P76; Cappellini MD, 2005, ANN NY ACAD SCI, V1054, P317, DOI 10.1196-annals.1345.039; Cappellini MD, 2010, ANN NY ACAD SCI, V1202, P231, DOI 10.1111-j.1749-6632.2010.05548.x; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; Chen SQ, 1996, AM J PHYSIOL-HEART C, V270, pH1951; ELDOR A, 1991, BLOOD, V77, P1749; Eldor A, 2002, BLOOD, V99, P36, DOI 10.1182-blood.V99.1.36; Gillis S, 1999, HAEMATOLOGICA, V84, P959; Kuypers FA, 2004, CELL MOL BIOL, V50, P147; Manfre L, 1999, AM J ROENTGENOL, V173, P1477; MICHAELI J, 1992, ACTA HAEMATOL-BASEL, V87, P71; Musallam KM, 2011, HEMOGLOBIN, V35, P503, DOI 10.3109-03630269.2011.605499; Musallam KM, 2011, EUR J HAEMATOL, V87, P539, DOI 10.1111-j.1600-0609.2011.01706.x; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160-TH06-05-0267; Taher AT, 2008, BLOOD REV, V22, P283, DOI 10.1016-j.blre.2008.04.001; Taher AT, 2010, J THROMB HAEMOST, V8, P2152, DOI 10.1111-j.1538-7836.2010.03940.x; Taher AT, 2010, J THROMB HAEMOST, V8, P54, DOI 10.1111-j.1538-7836.2009.03651.x; Taher AT, 2010, BLOOD, V115, P1886, DOI 10.1182-blood-2009-09-243154; Tavazzi D, 2001, BRIT J HAEMATOL, V112, P48, DOI 10.1046-j.1365-2141.2001.02482.x; Tripodi A, 2009, HAEMATOL-HEMATOL J, V94, P1520, DOI 10.3324-haematol.2009.010546; WIJBURG FA, 1988, EUR J PEDIATR, V147, P444, DOI 10.1007-BF0049643558
Donde no habite el olvido. Herencia y transmisión del testimonio en Chile
No full text¿Cuál es la función del testigo frente a las políticas del estado? ¿Cuáles son las instancias que definen la producción y recepción de su palabra? ¿Cómo visibilizar las huellas del testimonio en una realidad amnésica, cada vez más condicionada por el mercado? En la encrucijada entre el territorio jurídico-político y literario, los textos aquí reunidos se proponen desvelar el ‘secreto’ de la praxis testimonial, iluminando una serie de obras narrativas que describen los contextos chilenos entre el 1973, año tristemente célebre por el comienzo de la dictadura, y el 2015. La vozde los testigos (Hernán Valdés, Jorge Montealegre, Rolando Carrasco), la reparación autobiográfica del dolor (Guillermo Núñez) y la traducción en palabra poética de la resistencia al horror y la violencia (Raúl Zurita, Diamela Eltit) se suman a la mediación de la memoria por parte de actores secundarios que, en el proceso de ‘narrativización’, exponen el pasado a nuevas instancias discursivas, reposicionando y redefiniendo sus contornos (Carlos Franz, Fátima Sime, Lucía Guerra).El conjunto de ensayos refleja una aproximación a lo testimonial como ejercicio de búsqueda siempre inacabado, que se realiza en la apertura hacia el otro, en la asunción de sus instancias, en la inclusión, siempre inacabada, en su universo.Textos de: Ksenija Bilbija; Claudia Borri; Martina Bortignon; Lilianet Brintrup; Giuliana Calabrese; Serena Cappellini; Rubí Carreño Bolívar; Rose Corral; Diamela Eltit; Maria Alessandra Giovannini; Gladys Ilarregui; Isabel Lipthay; Naín Nómez; Jaume Peris Blanes; Carolina Pizarro Cortés; José Santos Herceg; Laura Scarabelli; Marianna Scaramucci
Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?
No full text[No abstract available]Camaschella C, 1997, AM J HEMATOL, V55, P83, DOI 10.1002-(SICI)1096-8652(199706)55:283::AID-AJH63.3.CO;2-M; Cappellini MD, 2010, ANN NY ACAD SCI, V1202, P231, DOI 10.1111-j.1749-6632.2010.05548.x; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; Harteveld CL, 2008, BLOOD CELL MOL DIS, V40, P312, DOI 10.1016-j.bcmd.2007.11.006; Harteveld CL, 2005, J MED GENET, V42, P922, DOI 10.1136-jmg.2005.033597; MANNU F, 1995, BLOOD, V86, P2014; SAMPIETRO M, 1983, BRIT J HAEMATOL, V55, P709, DOI 10.1111-j.1365-2141.1983.tb02854.x; SHINAR E, 1990, SEMIN HEMATOL, V27, P70; Sollaino MC, 2009, HAEMATOL-HEMATOL J, V94, P1445, DOI 10.3324-haematol.2009.005728; Taher AT, 2011, BRIT J HAEMATOL, V152, P512, DOI 10.1111-j.1365-2141.2010.08486.x; Taher AT, 2010, J THROMB HAEMOST, V8, P2152, DOI 10.1111-j.1538-7836.2010.03940.x11
Red blood cell enzyme disorders: An overview
No full text[No abstract available]Baronciani L, 1998, Blood Cells Mol Dis, V24, P273, DOI 10.1006-bcmd.1998.0193; BATTISTUZZI G, 1985, P NATL ACAD SCI USA, V82, P1465, DOI 10.1073-pnas.82.5.1465; BEUTLER E, 1992, ACTA HAEMATOL-BASEL, V87, P103; Beutler E, 1996, BLOOD REV, V10, P45, DOI 10.1016-S0268-960X(96)90019-3; Beutler E, 1984, RED CELL METABOLISM, p[3, 78]; BIENZLE U, 1972, LANCET, V1, P107; Bulliamy T, 1997, Blood Cells Mol Dis, V23, P302; Cappellini MD, 1999, BRIT J HAEMATOL, V104, P928; Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016-S0140-6736(08)60073-2; DACIE J, 1985, HEMOLYTIC ANEMIAS, V1, P284; DERN RJ, 1954, J LAB CLIN MED, V44, P171; DiMontemuros FM, 1997, HAEMATOLOGICA, V82, P440; Edwards Corwin Q, 2002, Clin Liver Dis, V6, P891, DOI 10.1016-S1089-3261(02)00050-8; Fiorelli G, 2000, BEST PRACT RES CL HA, V13, P39, DOI 10.1053-beha.1999.0056; GAETANI GD, 1974, P NATL ACAD SCI USA, V71, P3584, DOI 10.1073-pnas.71.9.3584; HAFEZ M, 1986, J PEDIATR, V108, P558, DOI 10.1016-S0022-3476(86)80833-2; Hirono A, 2002, BLOOD, V99, P1498, DOI 10.1182-blood.V99.4.1498; Jacobasch G, 2000, BEST PRACT RES CL HA, V13, P1, DOI 10.1053-beha.2000.0054; KANNO H, 1992, BIOCHEM BIOPH RES CO, V188, P516, DOI 10.1016-0006-291X(92)91086-6; Kaplan M, 1996, J PEDIATR, V128, P695, DOI 10.1016-S0022-3476(96)80138-7; Kayne F.J., 1973, ENZYMES, V8, P353; LESTAS AN, 1990, BLOOD REV, V4, P148, DOI 10.1016-0268-960X(90)90042-Q; Luzzatto L, 2001, METABOLIC MOL BASES, P4517; Mason PJ, 1996, BRIT J HAEMATOL, V94, P585; Mehta A, 2000, BEST PRACT RES CL HA, V13, P21, DOI 10.1053-beha.1999.0055; Mentzer W. C., 1989, HEREDITARY HEMOLYTIC, P267; NAKASHIMA K, 1977, J LAB CLIN MED, V90, P1012; NEWMAN TB, 1992, PEDIATRICS, V89, P809; Ruwende C, 1998, J MOL MED-JMM, V76, P581, DOI 10.1007-s001090050253; TANAKA KR, 1990, METABOLIC MOL BASIS, P3485; TANI K, 1988, P NATL ACAD SCI USA, V85, P1792, DOI 10.1073-pnas.85.6.1792; TANI K, 1994, BLOOD, V83, P2305; Tanphaichitr VS, 2000, BONE MARROW TRANSPL, V26, P689, DOI 10.1038-sj.bmt.1702576; TOWN M, 1992, HUM MOL GENET, V1, P171, DOI 10.1093-hmg-1.3.171; VALENTINE W, 1961, T ASSOC AM PHYSICIAN, V74, P100; VALENTINE WN, 1985, ANN INTERN MED, V103, P245; WHO Working Group, 1989, B WORLD HEALTH ORGAN, V67, P601; Zanella A, 2005, BRIT J HAEMATOL, V130, P11, DOI 10.1111-j.1365-2141.2005.05527.x; ZANELLA A, 1993, BRIT J HAEMATOL, V83, P485, DOI 10.1111-j.1365-2141.1993.tb04675.x; Zanella A, 2001, BLOOD CELL MOL DIS, V27, P653, DOI 10.1006-bcmd.2001.043354
Beta-thalassemia intermedia: An overview
No full text[No abstract available]Aessopos A, 2005, CHEST, V127, P1523, DOI 10.1378-chest.127.5.1523; Aessopos A, 2001, BLOOD, V97, P3411, DOI 10.1182-blood.V97.11.3411; CAPELLINI MD, 2002, HEMATOL J, V65; CAPELLINI MD, 2007, GUIDELINES CLIN MANA, pCH11; Cappellini MD, 2005, SEMIN HEMATOL, V42, pS19, DOI 10.1053-j.seminhematol.2005.01.001; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; Castelli R, 2004, AM J MED SCI, V328, P299, DOI 10.1097-00000441-200411000-00012; Chehal Aref, 2003, Spine (Phila Pa 1976), V28, pE245, DOI 10.1097-00007632-200307010-00024; Dixit A, 2005, ANN HEMATOL, V84, P441, DOI 10.1007-s00277-005-1026-4; Eldor A, 2002, BLOOD, V99, P36, DOI 10.1182-blood.V99.1.36; GIMMON Z, 1982, PLAST RECONSTR SURG, V69, P320, DOI 10.1097-00006534-198202000-00023; Karimi M, 2005, J PEDIAT HEMATOL ONC, V27, P380, DOI 10.1097-01.mph.0000174386.13109.28; Kushner J P, 2001, Hematology Am Soc Hematol Educ Program, P47; Mourad FH, 2003, BRIT J HAEMATOL, V121, P187, DOI 10.1046-j.1365-2141.2003.04240.x; Origa R, 2005, ANN NY ACAD SCI, V1054, P451, DOI 10.1196-annals.1345.051; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056-NEJM199301143280202; St Pierre TG, 2005, BLOOD, V105, P855, DOI 10.1182-blood-2004-01-0177; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160-TH06-05-0267; TAHER A, 2006, BLOOD CELL MOL DIS, V27, P12; TAHER A, 2007, ASH ANN M, V110, P3818; Weatherall DJ, 2001, J HEMATOL S1, V86, P18694
- …
